Monday, January 12, 2015

Postmenopausal Estrogen Therapy Reduces Glaucoma Risk

Postmenopausal hormone therapy may have an added benefit of reducing your risk of developing glaucoma. Researchers reporting a study in JAMA Ophthalmology found that taking estrogen only postmenopausal hormone (PMH) treatment may help specifically reduce the risk for primary open-angle glaucoma (POAG), the most common type of glaucoma. By reviewing data from 152,163 women 50 years or older the researchers found that 1.9 percent of enrollees developed POAG. Each additional month of use of PMH containing estrogen only was associated with a 0.4 percent reduced risk for POAG whereas each additional month of use of estrogen + progesterone or estrogen + androgen hormones did not affect risk for POAG. This is interesting information and will most likely be the subject of future research to understand how it might be used to develop new treatment options for primary open angle glaucoma (POAG).

If you or someone you know is concerned about glaucoma, has any risk factors for glaucoma or needs to schedule a glaucoma eye exam please call Alabama Eye & Cataract Center at 205-930-0930, visit Alabama Eye & Cataract Center or

Alabama Eye & Cataract Center is leading eye care center in Birmingham located at UAB-Highlands, 1201 11th Avenue S, Suite 501, Birmingham, Alabama 35205